Warburg Pincus has announced the acquisition of Integrace Private Limited, a leading domestic formulations company focused on orthopedics and gynecology. Cyril Amarchand Mangaldas advised Warburg Pincus on the Warburg Pincus Integrace acquisition, deploying a multi-practice team spanning transactions, regulatory, IP, employment, and competition law. The transaction marks the complete exit of existing investors True North and Temasek Holdings, who had backed the company during its expansion phase.
Introduction
The deal sees Warburg Pincus acquire Integrace Private Limited, a leading domestic formulations company focused on orthopedics and gynecology. True North and Temasek fully exited Integrace, where they jointly held a 99.74% stake. Integrace has built a differentiated portfolio of more than 20 brands across attractive high-growth markets, and through its scientific marketing practices has built trusted relationships with over 45,000 healthcare professionals across India.
Industry veteran Rehan Khan, former Managing Director at MSD and Abbott India Limited, will join Integrace as Chief Executive Officer to lead the company’s next phase of growth in partnership with Warburg Pincus.
Deal Value
The acquisition of Integrace Private Limited is valued at approximately ₹1,200 crore, strengthening Warburg Pincus’s footprint in India’s fast-growing pharmaceutical sector.
Legal Teams Involved
Cyril Amarchand Mangaldas advised Warburg Pincus on the transaction. The firm fielded six specialist sub-teams across the full breadth of the deal.
Strategic Guidance
- Reeba Chacko, Senior Partner
Transaction Team
- Vandana Sekhri, Partner (team lead)
- Siddharth Vedula, Partner
- Dhrumil Sanghvi, Principal Associate
- Ayushi Jhawar, Associate
Due Diligence Team
- Vandana Sekhri, Partner (team lead)
- Arun Prabhu, Partner – (Co-Head – Digital | TMT) (team lead)
- Siddharth Vedula, Partner
- Dhrumil Sanghvi, Principal Associate
- Ayushi Jhawar, Associate
Regulatory Advisory Team
- Vandana Sekhri, Partner (team lead)
- Arun Prabhu, Partner – (Co-Head – Digital | TMT) (team lead)
- Subhankar Pasalapudi, Partner
- Princy D’souza, Associate
Intellectual Property, Information Technology and Data Protection Diligence and Advisory Team
- Arun Prabhu, Partner – (Co-Head – Digital | TMT) (team lead)
- Arpita Sengupta, Partner (team lead)
- Mansi Jain, Associate
- Princy D’souza, Associate
- Pooja Bommareddy, Associate
Pharmaceutical Regulatory Diligence and Advisory Team
- Arun Prabhu, Partner – (Co-Head – Digital | TMT) (team lead)
- Biplab Lenin, Partner (team lead)
- Anam Chowdhary, Associate
Employment Diligence and Advisory Team
- Krithika Radhakrishnan, Partner (team lead)
- Shivika Gupta, Senior Associate
ESOP Structuring and Transition Advisory Team
- Sindhushri Badarinath, Partner (team lead)
- Shubham Parkhi, Director – Corporate Practice
- Aarav Prasad, Associate
- Rashi Kabra, Associate
ABAC, AML and Sanctions Diligence and Advisory Team
- Sara Sundaram, Partner (team lead)
- Nikhil Kansal, Associate
- Irene Sarkar, Associate
Competition Law Advisory Team
- Avaantika Kakkar, Partner (Head – Competition) (team lead)
- Anshul Jain, Senior Consultant
Legal advisors to the sellers, True North and Temasek, were not disclosed.
Significance and Impact
The acquisition underscores Warburg Pincus’s strategy of building scaled, therapy-focused pharmaceutical platforms in India, where rising healthcare awareness, increasing incomes, and expanding access to quality healthcare continue to drive long-term market growth. The acquisition marks Warburg Pincus’s continued focus on India’s healthcare sector, where the firm has invested across pharmaceuticals, medical technology, and healthcare services over the past three decades.
From a legal standpoint, the breadth of the Cyril Amarchand Mangaldas advisory is notable — ten distinct practice sub-teams covering transaction structuring, multi-layered due diligence, pharmaceutical regulation, IP and data protection, employment, ESOP, ABAC/AML/sanctions compliance, and competition law were engaged simultaneously. This reflects the regulatory complexity inherent in pharmaceutical M&A in India, particularly for a company operating in specialist therapeutic segments. For a deal benchmarked against comparable pharma transactions, see Deal Meter.
A significant part of Integrace’s business model has involved the strategic acquisition of established products from other pharmaceutical companies, including previous deals involving Zydus and Glenmark, adding further layers of IP chain-of-title and regulatory diligence to the transaction.
The Warburg Pincus Integrace acquisition represents a significant private equity bet on India’s branded pharmaceutical formulations sector, with Cyril Amarchand Mangaldas providing comprehensive multi-disciplinary legal coverage across the full transaction lifecycle. Existing shareholders True North and Temasek fully exit their investment in the company as part of the transaction. The deal, valued at approximately ₹1,200 crore, positions Integrace for its next phase of growth under new leadership.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
